InsidersTradesSigma
Total declarations
Companies
▲ Purchases (5 ops.)
▼ Sales (5 ops.)
Insider track record
Board DirectorDisclosed buys
5
Disclosed sells
5
T+90 hit rate
6%
T+90 mean return
-31.0%
Across 17 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Behbahani Ali, Director. Director active across 17 companies, notably Oyster Point Pharma, Inc.. Cumulatively, 54 filings have been logged. Split: 5 buys · 5 sells. Total volume traded: €10.7m. History available since 7 June 2021. The latest transaction was filed on 1 July 2026 (J). Regulator: SEC (Form 4). All data is free.
Declarations54 total
1,000,000 shares0Common StockSEC:0001193125-26-296490:0
15,000 shares0Common StockSEC:0001193125-26-296490:1
15,000 shares0Common StockSEC:0001193125-26-296490:2
8,961 sharesCommon StockSEC:0001193125-26-277553:0
1,925 sharesCommon StockSEC:0001193125-26-187305:0
2,706 sharesCommon StockSEC:0001193125-26-187305:1
4,828,206 shares@ US$0.01123.2% of flowOrdinary Shares with a nominal value of 0.001 GBP per shareSEC:0000950170-25-110254:0
14,671,794 shares@ US$0.01276.8% of flowOrdinary Shares with a nominal value of 0.001 GBP per shareSEC:0000950170-25-110254:1
7,646 shares@ US$1.880.3% of flowCommon StockSEC:0000950170-25-043221:0
5,750 shares@ US$2.500.3% of flowCommon StockSEC:0000950170-24-136739:0
3,007 shares@ US$4.780.3% of flowCommon StockSEC:0000950170-24-108430:0
1,023,103 sharesCommon StockSEC:0000950170-24-107554:0
2,887 shares@ US$4.980.3% of flowCommon StockSEC:0000950170-24-076273:0
17,857 shares@ US$56.00100.0% of flowCommon StockSEC:0000950170-24-047684:0
3,166 shares@ US$4.540.3% of flowCommon StockSEC:0000950170-24-041554:0
316 shares@ US$0.237100.0% of flowCommon StockSEC:0001209191-23-058968:0
4,455 shares@ US$2.730.2% of flowCommon StockSEC:0001209191-23-058790:0
1,072,936 sharesCommon StockSEC:0001209191-23-054637:0
3,299 shares@ US$3.600.2% of flowCommon StockSEC:0001209191-23-049791:0
333,333 shares@ US$3.00100.0% of flowCommon StockSEC:0001209191-23-042797:0
Ideal exit: 12 Apr 2024 (T+270)
1,000,000 shares@ US$5.0095.4% of flowCommon StockSEC:0001209191-23-041567:0
Ideal exit: 31 Mar 2024 (T+270)
5,655 shares@ US$2.100.2% of flowCommon StockSEC:0001209191-23-038084:0
2,000,000 shares0Common StockSEC:0001209191-23-037353:0
113 shares0Common StockSEC:0001209191-23-034387:0
7,111 shares@ US$1.670.2% of flowCommon StockSEC:0001209191-23-020051:0
25 of 54 declarations
About Behbahani Ali
Public sources indicate that Ali Behbahani, M.D., M.B.A., is a director at Black Diamond Therapeutics, Arcellx, and Adaptimmune Therapeutics, and that he has also served on the boards of Oyster Point Pharma, Minerva Surgical, and Trevi Therapeutics. They describe him as a partner, often co-head of healthcare, at New Enterprise Associates, with board service dating to February 2015 at Arcellx, December 2018 at Black Diamond Therapeutics, September 2014 at Adaptimmune, July 2017 at Oyster Point Pharma, and May 2011 at Minerva Surgical. The same sources also say he previously worked in healthcare investing at The Medicines Company, Morgan Stanley, and Lehman Brothers, and that he holds an M.D. from the University of Pennsylvania and an M.B.A. from Wharton. Sources : https://www.sec.gov/Archives/edgar/data/1703647/000119312523299978/d597314ds1a.htm
